Noh Sang Tae, Lee Hyoung Shin, Lim Soo Jin, Kim Sung Won, Chang Hee Kyung, Oh Junghwan, Jeon Chang-Ho, Park Jong Wook, Lee Kang Dae
Department of Otolaryngology-Head and Neck Surgery, Kosin University Graduate School, Busan, South Korea.
Department of Otolaryngology-Head and Neck Surgery, Kosin University College of Medicine, 34, Amnam-Dong, Seo-Gu, Busan, 602-715, Republic of Korea.
Int J Clin Oncol. 2016 Oct;21(5):875-882. doi: 10.1007/s10147-016-0989-6. Epub 2016 May 26.
Various subtypes of melanoma-associated antigens (MAGEs) are expressed in the tumor tissues of patients with head and neck squamous cell carcinoma (HNSCC). However, little data are currently available on how the gene expression of MAGEs impacts clinical patterns and oncologic outcomes. We have therefore evaluated the expression of MAGE-A1-6 (A1-6) subtypes in tumor tissues of patients with HNSCC and the clinical impact of this expression.
This was a retrospective review of 53 patients with histologically proven HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx who underwent both treatment and analysis by reverse transcription (RT)-PCR assay with a common primer to identify the expression of MAGE-A1-6 subtypes in the tumor tissue. The clinicopathologic factors and oncologic outcomes of these patients and the correlations of both to MAGE-A1-6 gene expression were analyzed.
MAGE-A1-6 subtypes were expressed in the tumor tissues of 37 patients (69.8 %). Patient age of ≥65 years [p = 0.031, hazard ratio (HR) 4.866] and advanced American Joint Committee on Cancer stage (p = 0.035, HR 4.291) were independent risk factors for expression of MAGE-A1-6 subtypes. Patients with MAGE-A1-6 expression had lower disease-free survival (p = 0.029), disease-specific survival (p = 0.070), and overall survival (p = 0.017) rates. Overall survival rate was independently associated to chemotherapy (p = 0.011, HR 2.859), while no surgery (p = 0.050, HR 2.400) and MAGE-A1-6 expression (p = 0.050, HR 2.527) showed borderline significance.
In our patient group the expression of MAGE-A1-6 subtypes in tumor tissues of patients with HNSCC was correlated with advanced clinical stage of cancer and poor oncologic outcomes. We suggest that gene expression of MAGE-A1-6 subtypes may be considered to be a predictive factor to determine patient treatment or follow-up strategy.
多种黑色素瘤相关抗原（MAGEs）亚型在头颈部鳞状细胞癌（HNSCC）患者的肿瘤组织中表达。然而，目前关于MAGEs基因表达如何影响临床模式和肿瘤学结局的数据很少。因此，我们评估了HNSCC患者肿瘤组织中MAGE-A1-6亚型的表达及其临床影响。
这是一项对53例经组织学证实为口腔、口咽、喉或下咽HNSCC患者的回顾性研究，这些患者均接受了治疗，并通过逆转录（RT）-PCR检测，使用通用引物来鉴定肿瘤组织中MAGE-A1-6亚型的表达。分析了这些患者的临床病理因素、肿瘤学结局以及二者与MAGE-A1-6基因表达的相关性。
37例患者（69.8%）的肿瘤组织中表达了MAGE-A1-6亚型。年龄≥65岁（p = 0.031，风险比[HR] 4.866）和美国癌症联合委员会晚期分期（p = 0.035，HR 4.291）是MAGE-A1-6亚型表达的独立危险因素。MAGE-A1-6表达的患者无病生存率（p = 0.029）、疾病特异性生存率（p = 0.070）和总生存率（p = 0.017）较低。总生存率与化疗独立相关（p = 0.011，HR 2.859），而未进行手术（p = 0.050，HR 2.400）和MAGE-A1-6表达（p = 0.050，HR 2.527）显示出临界显著性。
在我们的患者组中，HNSCC患者肿瘤组织中MAGE-A1-6亚型的表达与癌症的晚期临床分期和不良肿瘤学结局相关。我们建议，MAGE-A1-6亚型的基因表达可被视为确定患者治疗或随访策略的预测因素。
